AllSci News
Spyre's SPY001 meets primary endpoint in Phase II ulcerative colitis induction trial
Spyre Therapeutics (Nasdaq: SYRE) reported that SPY001, its extended half-life anti-α4β7 antibody, met the primary endpoint in the open-label Part A of the...
GSK's B7-H4 ADC set for 5 Phase III trials in gynecological cancers after strong Phase I
GSK (LSE/NYSE: GSK) reported Phase I data for mocertatug rezetecan, a B7-H4-targeted antibody-drug conjugate, showing confirmed objective response rates of...
BioNTech and DualityBio's trastuzumab pamirtecan hits endpoitn in Phase II for endometrial cancer
BioNTech (Nasdaq: BNTX) and DualityBio reported that trastuzumab pamirtecan met its primary endpoint in a Phase II cohort of 145 patients with...
EC adds pediatric indication for Sanofi/Regeneron’s Dupixent in chronic spontaneous urticaria
The European Commission has approved Dupixent (dupilumab) for moderate-to-severe chronic spontaneous urticaria in children aged two to 11 years, making it the…
AbbVie's Elahere demonstrates 62.7% response rate in platinum-sensitive ovarian cancer
AbbVie presented Phase II results for mirvetuximab soravtansine (ELAHERE) in folate receptor alpha (FRα)-positive, recurrent platinum-sensitive ovarian...
SynOx's CSF-1R antibody emactuzumab set for approval filing in TCGT after strong Phase III
SynOx Therapeutics reported that emactuzumab met both primary and secondary endpoints in the Phase III TANGENT study in tenosynovial giant cell tumor, with...
Grand Pharma's SIR-Spheres Y-90 aces endpoints in HCC Phase III
Grand Pharmaceutical Group (HKEX: 00512) announced that the DOORwaY90 trial of SIR-Spheres Y-90 resin microsphere injection in unresectable hepatocellular...
Revolution Medicines' daraxonrasib nearly doubles OS in Phase III pancreatic cancer trial
Revolution Medicines (Nasdaq: RVMD) reported that daraxonrasib nearly doubled median overall survival compared with standard chemotherapy in previously...
Hemab Therapeutics moving towards Nasdaq IPO
Hemab Therapeutics Holdings, Inc. filed a Form S-1 registration statement with the U.S. Securities and Exchange Commission for an initial public offering of...
Seaport Therapeutics files to for Nasdaq listing to support oral psychiatric therapies
Seaport Therapeutics filed an S-1 registration statement with the SEC for an initial public offering of common stock on the Nasdaq Global Market under the...
Eli Lilly's Jaypirca beats venetoclax-rituximab in Phase III for previously treated CLL
Eli Lilly (NYSE: LLY) reported that pirtobrutinib (Jaypirca) added to venetoclax and rituximab produced a statistically significant improvement in...
Everest acquires Hasten Biopharmaceuticals' Asia-Pacific platform for USD 250m
Everest Medicines Acquires Asia Pacific Commercial Platform for USD 250 Million via Hasten Biopharmaceuticals Deal
Allogene's off-the-shelf CD19 CAR-t clears MRD benchmark in Phase II LBCL trial
Allogene Therapeutics (Nasdaq: ALLO) reported interim futility data from its Phase II ALPHA3 trial showing that cemacabtagene ansegedleucel (cema-cel)...
Ideaya and Servier's darovasertib plus crizotinib meets Phase II/III endpoint in metastatic uveal melanoma
IDEAYA Biosciences (NASDAQ: IDYA) and Servier reported that darovasertib plus crizotinib met the primary endpoint of the Phase II/III OptimUM-02 trial,...
Replimune receives second CRL from FDA for oncolytic virus melanoma treatment
Replimune Group, Inc. (Nasdaq: REPL) announced on April 10, 2026 that the FDA issued a Complete Response Letter (CRL) for the company’s…
The AllSci Brief
Systematic R&D and deal news. Daily.